Alpine Woods Capital Investors’s Neurocrine Biosciences NBIX Stock Holding History

Alpine Woods Capital Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,710	Closed	-$264K	–	230
2021 Q2	$264K	Sell	2,710 -2,800	-51%	-$268K	0.03%	220
2021 Q1	$536K	Sell	5,510 -2,710	-33%	-$284K	0.06%	181
2020 Q4	$788K	Buy	+8,220	New	+$794K	0.1%	166

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Alpine Woods Capital Investors's NBIX Position: Q3 2021 in Review

Alpine Woods Capital Investors sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 2,710 shares — an estimated $264K sold.

Alpine Woods Capital Investors first reported a position in NBIX in Q4 2020 and held it in 3 quarters. The position peaked at $788K in Q4 2020. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

Alpine Woods Capital Investors reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
Alpine Woods Capital Investors sold 2,710 Neurocrine Biosciences shares in Q3 2021, an estimated $264K.
Alpine Woods Capital Investors first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 3 quarters.
Alpine Woods Capital Investors's Neurocrine Biosciences position peaked at $788K in Q4 2020.
396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Alpine Woods Capital Investors's 13F filing for Q3 2021, filed 12 Nov 2021.